# Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

> **NCT01846273** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 321 (actual)

## Conditions studied

- Age-related Macular Degeneration
- Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Verteporfin PDT
- **DRUG:** Sham PDT

## Key facts

- **NCT ID:** NCT01846273
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-07
- **Primary completion:** 2016-03-11
- **Final completion:** 2017-03-02
- **Target enrollment:** 321 (ACTUAL)
- **Last updated:** 2019-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01846273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01846273, "Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01846273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*